問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
楊慕華
下載
2020-08-14 - 2027-07-24
Condition/Disease
Test Drug
Participate Sites7Sites
Recruiting7Sites
2021-10-15 - 2024-06-13
Not yet recruiting2Sites
Recruiting5Sites
2024-04-10 - 2028-07-25
Participate Sites6Sites
Recruiting6Sites
2020-10-16 - 2024-04-30
Recurrent or metastatic solid tumor
BAY 73-4506 (Regorafenib)Nivolumab
Participate Sites3Sites
Recruiting3Sites
2025-02-17 - 2028-10-10
Participate Sites2Sites
Recruiting2Sites
2023-02-01 - 2027-06-30
Participate Sites4Sites
Recruiting4Sites
2019-01-01 - 2028-12-31
2022-11-18 - 2027-12-31
2024-03-01 - 2028-06-30
Participate Sites5Sites
2019-05-01 - 2025-12-31
Advance tumor
FLX475
全部
